Open Your Free Demat Account
Enjoy low brokerage on delivery trades
Max Healthcare is executing a structured expansion strategy centred on brownfield capacity additions, selective acquisitions, improving ARPOB, and disciplined capital deployment, supported by steady operating metrics and recent regulatory developments.
Particulars | Details |
Exchange | NSE / BSE |
NSE/BSE Code | MAXHEALTH / 543220 |
CMP (₹) | 1,078 |
Target Price (₹) | 1,218 |
Upside (%) | 12% |
52-Week High / Low (₹) | ₹1,314 / 940 |
Market Capitalisation | ₹1,055.46 bn |
Max Healthcare is in an ongoing expansion cycle with defined capacity additions supported by sustained improvement in operating performance, capital deployment aligned with reported ROCE metrics and balance-sheet discipline. The company’s strategy prioritises brownfield expansions, selective inorganic growth and calibrated greenfield development, enabling capacity addition without diluting return metrics.
Cumulative project capex of approximately ₹6,487 crore has been committed through FY29, significantly expanding the network’s potential capacity over the medium term. Despite the scale of expansion, return ratios remain strong, with network-level ROCE exceeding 28% and existing hospitals delivering nearly 38% ROCE. Net debt continues to be maintained below 1x EBITDA, providing flexibility for ongoing capital deployment.
Particulars | Q2FY26 | Q1FY26 | Q4FY25 |
Promoter | 23.74 | 23.74 | 23.74 |
FII | 51.80 | 54.76 | 54.74 |
DII | 20.03 | 17.41 | 17.49 |
Others | 4.43 | 4.09 | 3.94 |
Promoter Pledge – 0.44%
Brownfield projects and strategic acquisitions are expected to be the primary earnings drivers over FY26–FY28. The integration of Jaypee Healthcare (Noida) and Alexis Hospital (Nagpur) has accelerated scale while complementing high-margin brownfield expansions at Mohali, Nanavati-Max and Saket.
Management highlights that brownfield additions benefit from shared infrastructure and overhead absorption, limiting incremental EBITDA drag and enabling faster margin normalisation. Upcoming developments at Vikrant, Vaishali and Dehradun further strengthen the core northern cluster. This blend of inorganic growth and operating leverage is expected to translate into incremental contribution from FY27 onwards.
Alongside brownfield growth, Max Healthcare is executing a structured greenfield and asset-light expansion strategy. New hospitals at Gurugram Sector-56, Patparganj (Nirogi), Thane, Zirakpur, Pitampura and a new site in Lucknow expand the company’s geographic footprint beyond Delhi NCR and Mumbai.
These projects diversify volume pools and are critical to sustaining growth as mature hospitals operate at occupancy levels close to 80%. Different project structures allow the company to maintain capital efficiency while expanding capacity.
Existing hospitals continue to report strong throughput growth. Occupied bed days increased by 22% year-on-year in H1 FY26. Like-for-like ARPOB for hospitals operational prior to Q4 FY24 grew by approximately 6.8% year-on-year.
ARPOB growth is driven by a higher contribution from oncology, transplants and complex surgical procedures, along with an improving payer mix. International patients contribute disproportionately to ARPOB and average length of stay, reflecting higher ARPOB contribution from select patient segments.
Hospitals at Dwarka, Noida, Lucknow and Nagpur continue to scale, with visible headroom for improvement in occupancy, ARPOB and margins as they converge toward network averages. These units also strengthen feeder flows into metro quaternary centres.
The revision in Central Government Health Scheme (CGHS) tariffs effective October 2025 is expected to provide an annual revenue uplift of approximately ₹200 crore. Creating a margin impact as outlined by management commentary from FY27. Linked government schemes such as ECHS provide additional revenue visibility.
Adjacency businesses such as Max Lab and Max@Home continue to scale at a 15–30% CAGR with minimal capital intensity, enhancing ecosystem stickiness and return metrics.
Digital channels now contribute nearly 30% of network revenues, supporting patient acquisition, improving utilisation and lowering customer acquisition costs. Digital scale continues to strengthen operating leverage across the hospital network.
Metric | Q2 FY26 |
Network Operating EBITDA Margin | 26.9% |
Existing Hospitals EBITDA Margin | 27.5% |
H1 FY26 Network EBITDA Margin | 25.9% |
H1 FY26 Existing Hospitals Margin | 26.5% |
Dwarka Hospital EBITDA Margin | 15% at 81% occupancy |
Max Lab EBITDA Margin | 16% |
Physiotherapy Business EBITDA Margin | 20% |
Management reiterated that brownfield expansions are expected to turn margin-accretive quickly, avoiding the typical EBITDA drag associated with greenfield hospitals.
Particulars | FY26E | FY27E | FY28E |
Revenue (mn) | 1,02,658 | 1,27,478 | 1,49,816 |
EBITDA (mn) | 27,493 | 34,686 | 42,586 |
PAT (mn) | 16,785 | 21,689 | 27,472 |
EPS (mn) | 17.27 | 22.31 | 28.26 |
Growth (%) | |||
Revenue | 46.1 | 24.2 | 17.5 |
EBITDA | 48.7 | 26.2 | 22.8 |
PAT | 56.0 | 29.2 | 26.7 |
Margins (%) | |||
EBITDA | 26.8 | 27.2 | 28.4 |
PAT | 16.4 | 17.0 | 18.3 |
Valuation (x) | |||
P/E | 63.1 | 48.8 | 38.5 |
P/B | 9.8 | 8.3 | 7.0 |
EV/EBITDA | 44.4 | 35.1 | 28.1 |
DEBT/EQUITY | 0.3 | 0.2 | 0.1 |
ROCE (%) | 16.8 | 19.2 | 21.0 |
ROE (%) | 15.5 | 17.1 | 18.3 |
Income Statement | (Rs in mn) | ||
|---|---|---|---|
Particulars | FY26E | FY27E | FY28E |
Revenue from Operation | 1,02,658.2 | 1,27,477.5 | 1,49,816.2 |
COGS | 21,434.4 | 25,495.5 | 29,963.2 |
% of Sales | 20.9 | 20.0 | 20.0 |
Gross Profit | 81,223.8 | 1,01,982.0 | 1,19,852.9 |
Gross margin (%) | 79.1 | 80.0 | 80.0 |
Employee Benefit Exp | 17,036.8 | 21,338.0 | 24,499.7 |
Other expenses | 36,694.1 | 45,958.1 | 52,767.7 |
EBITDA | 27,493.0 | 34,686.0 | 42,585.5 |
EBITDA Margins (%) | 26.8 | 27.2 | 28.4 |
Other Income | 2,053.2 | 2,549.6 | 2,996.3 |
Depreciation | 4,960.9 | 5,622.6 | 6,046.8 |
EBIT | 24,585.2 | 31,612.9 | 39,535.0 |
EBIT Margins (%) | 23.9 | 24.8 | 26.4 |
Finance Cost | 1,902.2 | 1,902.2 | 1,902.2 |
Profit before tax | 22,683.0 | 29,710.7 | 37,632.8 |
Total Tax expenses | 5,897.6 | 8,021.9 | 10,160.9 |
Tax rate (%) | 26.0 | 27.0 | 27.0 |
Profit after tax | 16,785.4 | 21,688.8 | 27,472.0 |
PAT Margins | 16.4 | 17.0 | 18.3 |
Basic EPS | 17.3 | 22.3 | 28.3 |
Balance Sheet | (Rs in mn) | ||
Particulars | FY26E | FY27E | FY28E |
ASSETS | |||
Fixed Assets | 44,089.8 | 49,352.2 | 53,548.4 |
CWIP | 22,400.0 | 18,900.0 | 8,440.0 |
Goodwill | 37,145.6 | 41,579.1 | 45,114.4 |
Trade Receivable | 11,335.2 | 14,075.7 | 16,542.2 |
Inventories | 1,551.3 | 1,926.4 | 2,263.9 |
Financial Assets | 2,621.8 | 2,621.8 | 2,621.8 |
Cash and cash equivalent | 3,190.0 | 8,198.8 | 28,879.6 |
Other Assets | 43,930.0 | 51,011.5 | 56,133.3 |
Total Assets | 1,66,263.8 | 1,87,665.5 | 2,13,543.6 |
EQUITY | |||
Equity Share Capital | 9,721.4 | 9,721.4 | 9,721.4 |
Other Equity | 98,522.8 | 1,17,175.1 | 1,40,801.0 |
Total Equity | 1,08,244.2 | 1,26,896.5 | 1,50,522.4 |
Long Term Borrowings | 30,399.6 | 30,399.6 | 30,399.6 |
Short Term Borrowings | 7,644.9 | 7,644.9 | 7,644.9 |
Trade Payables | 11,724.2 | 14,473.6 | 16,725.8 |
Other Liabilities | 8,250.9 | 8,250.9 | 8,250.9 |
Total Liabilities | 58,019.6 | 60,769.0 | 63,021.2 |
Total Equity and Liabilities | 1,66,263.8 | 1,87,665.5 | 2,13,543.6 |
Cash Flow Statement | (Rs in mn) | ||
Particulars | FY26E | FY27E | FY28E |
Cash Flow from operating activities (OA) | |||
PBT | 22,683.0 | 29,710.7 | 37,632.8 |
Depreciation | 4,960.9 | 5,622.6 | 6,046.8 |
Operating Profit before WC change | 29,546.2 | 37,235.6 | 45,581.8 |
Changes in Assets and liability | (418.8) | (366.2) | (551.9) |
Cash from Operations | 29,127.4 | 36,869.4 | 45,029.9 |
Tax | (5,897.6) | (8,021.9) | (10,160.9) |
Net Cash from OA | 23,229.8 | 28,847.5 | 34,869.1 |
Cash Flow from investing activities (IA) | |||
Capex | (22,400.0) | (18,900.0) | (8,440.0) |
Net Cash from IA | 0.0 | 0.0 | 0.0 |
Cash Flow from financing activities (FA) | |||
Finance Cost | (1,902.2) | (1,902.2) | (1,902.2) |
Dividend | (2,350.0) | (3,036.4) | (3,846.1) |
Net Cash from FA | (4,252.2) | (4,938.7) | (5,748.3) |
Net increase/(decrease) in Cash | (3,422.4) | 5,008.8 | 20,680.8 |
Cash at the beginning of the year | 6,612.4 | 3,190.0 | 8,198.8 |
Cash at the end of the year | 3,190.0 | 8,198.8 | 28,879.6 |
Ratio Analysis | |||
Particulars | FY26E | FY27E | FY28E |
Growth (%) | |||
Revenue | 46.1 | 24.2 | 17.5 |
Gross Profit | 46.3 | 25.6 | 17.5 |
EBITDA | 48.7 | 26.2 | 22.8 |
EBIT | 53.3 | 31.0 | 26.7 |
PAT | 56.0 | 29.2 | 26.7 |
% Of Revenue | |||
Gross Profit | 79.1 | 80.0 | 80.0 |
EBITDA | 26.8 | 27.2 | 28.4 |
EBIT | 23.9 | 24.8 | 26.4 |
PAT | 16.4 | 17.0 | 18.3 |
Return Ratios (%) | |||
ROCE | 16.8 | 19.2 | 21.0 |
ROE | 15.5 | 17.1 | 18.3 |
Valuation (x) | |||
P/E | 63.1 | 48.8 | 38.5 |
P/B | 9.8 | 8.3 | 7.0 |
EV/EBITDA | 44.4 | 35.1 | 28.1 |
EV/ Sales | 11.9 | 9.5 | 8.0 |
DEBT/EQUITY | 0.3 | 0.2 | 0.1 |
Parameter | Update |
CGHS Tariff Impact | ₹200+ crore benefit |
EBITDA Flow-through | 85–90% by FY27 |
ARPOB Growth (Existing Units) | 7% YoY |
International Patient ARPOB | 30% higher than average |
Temporary cashless-facility issues with insurers have been resolved, with future price revisions successfully negotiated.
Item | Details |
H1 FY26 Capex | ₹891 crore |
Land & Brownfield Additions | ₹131 crore |
H2 FY26 Capex Guidance | ₹1,100 crore |
Upcoming Capacity Additions
Project | Status |
Nanavati-Max | 268-bed tower commissioning mid-November |
Max Smart Hospital | 400-bed tower commissioning shortly |
Mohali | 160-bed tower commissioned |
Thane | Master plan finalised |
Pitampura (Delhi) | Building approvals awaited |
Item | Update |
Subsidiary Merger | Crosslay Remedies merged with Jaypee Healthcare |
One-Time Benefit | ₹149 crore |
Asset Divestment | Chitta and Anoopshahr hospitals divested |
Dividend Paid (Q2 FY26) | ₹146 crore |
Max Healthcare’s expansion pipeline includes phased brownfield additions, new greenfield hospitals and asset-light facilities across major metros and emerging clusters. As newer hospitals ramp up and utilisation improves, the EBITDA base is expected to expand meaningfully by FY28. Applying a 28x EV/EBITDA multiple to FY28 earnings implies a target price of ₹1,218, representing an upside of 12% from current levels.
Conclusion
Max Healthcare’s disclosures indicate a measured expansion phase anchored in brownfield-led capacity addition and selective inorganic growth, aimed at preserving return metrics and operating efficiency. Mature hospitals continue to support margins, while newer units offer visibility on incremental utilisation gains. Capital allocation remains aligned with leverage thresholds, and contributions from digital channels and adjacency businesses add diversification. Execution of the expansion pipeline, occupancy ramp-up, and regulatory implementation remain the primary operational variables to monitor.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading